448 Studies Now Enrolling
A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Alle
A study for patients with Cystic Fibrosis using study drug VX-661
| Sponsor: | Vertex Pharmaceuticals Incorporated |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ8846 |
| U.S. Govt. ID: | NCT02412111 |
| Contact: | Emily DiMango: 212-305-0631 / ead3@cumc.columbia.edu |
Additional Study Information:
This study is being done to learn more about the safety and effects of the combination of VX-661 and ivacaftor in subjects with Cystic Fibrosis (CF).
This study is closed
